The Global Niraparib Tosylate Market was valued at USD 846.7 Million in 2024 and is projected to reach USD 1.28 Billion by 2025, growing at a Compound Annual Growth Rate (CAGR) of 9.7% during the initial forecast period. The market is further expected to expand to USD 2.15 Billion by 2032. This robust growth is primarily driven by the rising global prevalence of ovarian and prostate cancers, expanded FDA approvals for new indications, and the accelerating adoption of PARP inhibitor therapies as a standard of care in precision oncology.

As the oncology landscape increasingly shifts toward targeted treatments and personalized medicine, the focus intensifies on the key pharmaceutical companies that are driving innovation, manufacturing scale, and therapeutic advancement. In this analysis, we profile the Top 10 Companies in the Niraparib Tosylate Industry—a mix of originator innovators, API manufacturing giants, and emerging generic players shaping the future of cancer treatment.

Download FREE Sample Report:
2025-2032 Global and Regional Niraparib Tosylate Industry Status and Prospects Professional Market – View in Detailed Research Report

---

🔟 1. Teva Pharmaceutical Industries Ltd.

Headquarters: Tel Aviv, Israel
Key Offering: Niraparib Tosylate API, Generic Formulations

Teva is a global leader in generic pharmaceuticals and active pharmaceutical ingredients (APIs), holding a significant position in the Niraparib Tosylate supply chain. The company’s robust API manufacturing capabilities and extensive global distribution network make it a critical supplier for both branded and generic versions of the drug. Teva’s pharmaceutical segment growth, which reported a 4.2% increase in 2024, is partly attributed to its strong portfolio of oncology drugs, including key components like Niraparib.

Strategic Initiatives:

• Expansion of high-potency API (HPAPI) manufacturing capacity

• Strategic partnerships for developing next-generation PARP inhibitors

• Investment in continuous manufacturing technologies for improved efficiency

---

9️⃣ 2. Zhejiang Tuopu Pharmaceutical Co., Ltd.

Headquarters: Taizhou, Zhejiang, China
Key Offering: Niraparib Tosylate API, Intermediate Chemicals

Zhejiang Tuopu has emerged as a dominant force in the Asian pharmaceutical market, capturing approximately 18% of the regional API market share for oncology drugs. The company invested $35 million in 2023 to expand its GMP-compliant production facilities, specifically targeting the manufacturing of PARP inhibitors. Its strategic focus on cost-effective production and supply chain optimization positions it as a key player for both domestic Chinese and international markets.

Strategic Initiatives:

• Enhanced R&D focus on oncology APIs and intermediates

• Secured three new international regulatory approvals for Niraparib formulations in Q1 2025

---

8️⃣ 3. ScinoPharm Taiwan, Ltd.

Headquarters: Taipei, Taiwan
Key Offering: High-Purity Niraparib Tosylate API, Custom Synthesis

ScinoPharm Taiwan is recognized as a premium API supplier with a strong focus on oncology therapeutics. The company specializes in the development and manufacturing of high-quality APIs, with Niraparib Tosylate accounting for approximately 12% of its oncology portfolio revenue. ScinoPharm’s commitment to stringent quality control and regulatory compliance has made it a preferred partner for pharmaceutical companies worldwide seeking reliable API sources.

Strategic Initiatives:

• Implementation of advanced analytical techniques for quality assurance

• Expansion of regulatory filings in emerging markets

Download FREE Sample Report:
2025-2032 Global and Regional Niraparib Tosylate Industry Status and Prospects Professional Market – View in Detailed Research Report

---

7️⃣ 4. GlaxoSmithKline (GSK)

Headquarters: London, United Kingdom
Key Offering: Zejula® (Branded Niraparib)

GSK is the originator and primary innovator behind Niraparib, marketing it under the brand name Zejula®. The company has driven extensive clinical development, resulting in FDA approvals for ovarian cancer maintenance therapy and expanded indications for prostate cancer. GSK’s strong commercial infrastructure and medical affairs capabilities have been instrumental in establishing Niraparib as a standard-of-care treatment in multiple therapeutic areas.

Strategic Initiatives:

• Ongoing clinical trials for combination therapies

• Global market access and reimbursement strategies

• Patient support programs to enhance treatment adherence

---

6️⃣ 5. Dr. Reddy’s Laboratories Ltd.

Headquarters: Hyderabad, Telangana, India
Key Offering: Generic Niraparib Tosylate, API Supply

Dr. Reddy’s is a leading global pharmaceutical company with strong capabilities in developing and manufacturing generic formulations. The company has been actively working on bioequivalent versions of Niraparib, positioning itself to capitalize on the upcoming patent expirations. With extensive experience in regulated markets and emerging economies, Dr. Reddy’s is well-equipped to address the growing global demand for affordable cancer treatments.

Strategic Initiatives:

• Development of cost-effective generic formulations

• Strategic focus on oncology portfolio expansion

---

5️⃣ 6. Hetero Drugs Limited

Headquarters: Hyderabad, Telangana, India
Key Offering: Niraparib Tosylate API and Formulations

Hetero Drugs is one of India’s largest generic pharmaceutical companies with a significant presence in the global API market. The company has established robust manufacturing capabilities for complex molecules like Niraparib Tosylate, focusing on quality and affordability. Hetero’s vertically integrated operations and scale enable it to compete effectively in both developed and emerging markets.

Strategic Initiatives:

• Capacity expansion for oncology APIs

• Partnerships with global generic companies

---

4️⃣ 7. Mylan N.V. (Part of Viatris)

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Generic Oncology Products, API Supply

Mylan, now part of Viatris, brings extensive experience in generic drug development and global supply chain management to the Niraparib market. The company’s strong regulatory expertise and distribution network position it as a significant player as the market prepares for generic entry post-2028. Mylan’s focus on making quality medicines accessible aligns with the need for affordable cancer treatments worldwide.

Strategic Initiatives:

• Portfolio optimization in high-value therapeutic areas

• Strategic planning for patent expiry opportunities

Download FREE Sample Report:
2025-2032 Global and Regional Niraparib Tosylate Industry Status and Prospects Professional Market – View in Detailed Research Report

---

3️⃣ 8. Sun Pharmaceutical Industries Ltd.

Headquarters: Mumbai, Maharashtra, India
Key Offering: Specialty and Generic Formulations

Sun Pharma is the largest pharmaceutical company in India and has a growing presence in the global oncology market. The company’s strong R&D capabilities and manufacturing expertise make it a formidable player in the Niraparib space. Sun Pharma’s focus on specialty pharmaceuticals and complex generics positions it well to develop advanced formulations of Niraparib that may offer improved patient benefits.

Strategic Initiatives:

• Investment in specialty oncology pipeline

• Global regulatory strategy implementation

---

2️⃣ 9. Jiangsu Hengrui Medicine Co., Ltd.

Headquarters: Lianyungang, Jiangsu, China
Key Offering: Innovative Drugs and APIs

Jiangsu Hengrui is a leading Chinese pharmaceutical company with a strong focus on innovative drug development. While primarily known for its proprietary oncology pipeline, the company also has capabilities in API manufacturing and is positioned to participate in the Niraparib market as it evolves. Hengrui’s significant R&D investments and manufacturing scale make it an important player in the Asian pharmaceutical landscape.

Strategic Initiatives:

• R&D focus on targeted cancer therapies

• Expansion of international business operations

---

1️⃣ 10. Cambrex Corporation

Headquarters: East Rutherford, New Jersey, USA
Key Offering: API Development and Manufacturing Services

Cambrex is a leading contract development and manufacturing organization (CDMO) specializing in APIs. The company provides comprehensive services from development through commercial manufacturing for pharmaceutical companies, including those marketing Niraparib. Cambrex’s expertise in handling complex molecules and regulatory support makes it a valuable partner for companies seeking to develop or manufacture Niraparib Tosylate.

Strategic Initiatives:

• Capacity expansion for highly potent active pharmaceutical ingredients (HPAPIs)

• Investment in continuous manufacturing technologies

Read Full Report:
2025-2032 Global and Regional Niraparib Tosylate Industry Status and Prospects Professional Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Niraparib Tosylate Is Precision and Accessibility

The Niraparib Tosylate market is undergoing a significant transformation as it moves from a novel therapy to an established treatment option. While the originator product continues to demonstrate strong clinical value, the industry is preparing for the impact of generic competition and exploring new therapeutic combinations and indications.

📈 Key Trends Shaping the Market:

• Accelerated generic development ahead of patent expirations starting in 2028

• Expansion into new cancer indications including prostate and pancreatic cancers

• Development of combination therapies with immunotherapy agents

• Increasing focus on biomarker-driven treatment selection and personalized medicine

Read Full Report:
2025-2032 Global and Regional Niraparib Tosylate Industry Status and Prospects Professional Market – View in Detailed Research Report

The companies profiled above are not only supplying critical cancer therapeutics—they’re driving the evolution of precision oncology and working to make advanced treatments more accessible to patients worldwide.